V67A.F COSMOS HEALTH NEW DL-01
- Market cap
- EUR 20.8M
- P/E
- -
- P/B
- 1.02x
- ROE
- -86.0%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is V67A.F undervalued?
Graham numberThe Graham number of COSMOS HEALTH NEW DL-01 cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
COSMOS HEALTH NEW DL-01 fundamental analysis
No fundamental analysis for COSMOS HEALTH NEW DL-01 yet.
COSMOS HEALTH NEW DL-01 stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About COSMOS HEALTH NEW DL-01
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), H…
Full company profileCOSMOS HEALTH NEW DL-01 financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
COSMOS HEALTH NEW DL-01 annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 56.2M | 50.3M | 53.4M | 54.4M | 65.3M | 73.8M |
| Gross Profit | 8.33M | 5.96M | 4.35M | 4.31M | 7.90M | 5.79M |
| Operating Income | -4.53M | -7.47M | -21.8M | -15.3M | -16.5M | -10.2M |
| EBITDA | - | -8.90M | -17.1M | -13.9M | -15.2M | -12.8M |
| Net Income | -7.96M | -13.8M | -18.5M | -16.2M | -19.1M | -17.8M |
| EPS | -12 | -1.31 | -1.17 | -0.69 | -0.51 | -0.22 |
| Balance Sheet | ||||||
| Total Assets | 49.4M | 68.0M | 66.0M | 54.3M | 65.5M | 61.5M |
| Total Liabilities | 45.0M | 28.4M | 30.0M | 29.8M | 47.1M | 40.8M |
| Shareholders' Equity | 4.38M | 39.7M | 36.0M | 24.5M | 18.4M | 20.7M |
| Cash & Short-term Investments | 286K | 20.7M | 3.83M | 315K | 716K | 1.80M |
| Cash Flow | ||||||
| Operating Cash Flow | -7.10M | -14.9M | -15.6M | -7.72M | -8.45M | -5.57M |
| Capital Expenditure | 891K | 383K | 9.17M | 1.27M | 153K | 188K |
| Free Cash Flow | -7.99M | -15.3M | -24.8M | -8.98M | -8.60M | -5.76M |
| Ratios | ||||||
| ROE | -181.8% | -34.9% | -51.4% | -66.0% | -103.9% | -86.0% |
| ROA | -16.1% | -20.3% | -28.1% | -29.8% | -29.2% | -28.9% |
| Net Profit Margin | -14.2% | -27.5% | -34.7% | -29.7% | -29.3% | -24.1% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
COSMOS HEALTH NEW DL-01 dividends
COSMOS HEALTH NEW DL-01 has not paid dividends in the last 5 fiscal years.
Last stock split: 1:25 on Dec 16, 2022.
Who owns COSMOS HEALTH NEW DL-01
- Insiders 24.27%
- Institutions 3.75%
- Public & others 71.98%
- Shares outstanding 101M
- Free float 76.2M
COSMOS HEALTH NEW DL-01 company profile
- Company name
- COSMOS HEALTH NEW DL-01
- Ticker
- V67A.F
- Exchange
- Frankfurt Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 163
- Fiscal year end
- December
- Address
- 5 Agiou Georgiou Str, Pilea, Thessaloniki, Greece, 55438
- Phone
- 312 536 3102
- Website
- cosmoshealthinc.com
About COSMOS HEALTH NEW DL-01
Cosmos Health Inc. manufactures, develops, and trades branded nutraceutical products in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, Albania, North Macedonia, and Cyprus. The company provides prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, cosmetics and other healthcare products under the Sky Premium Life and Mediterranation brand names. It offers ASTO-CHOL (Pravastatin), Diorium (Omeprazole), HEART-FREE (Clopidogrel), LIPICHOL (Atorvastatin), Miltus (Donepezil), Newzypra (Olanzapine), PNEUMO-KAST (Montelukast), Sahar (Pioglitazone), VIVALCID (Leucovorin), and Diabit-is (Sitagliptin). In addition, the company offers branded biocides and antiseptic soaps under the C-Sept and C-Scrub brand names; and other pharmaceutical products include Melatonin Spray, used to reduce insomnia and jet lag; Otikon ear drops, which is a Class II medical device in the form of ear drops; and baby foods, such as organic powder milk, pasta with minced meat, whole grain rice cereals, whole grain cereal porridges, and organic rice creams with vanilla milk, as well as pear, carrot and banana purée under the Bio-bebe brand. It serves wholesalers and retail healthcare providers. The company was founded in 2009 and is headquartered in Thessaloniki, Greece.
COSMOS HEALTH NEW DL-01 management
5- Mr. Grigorios SiokasChairman & CEO · born 1965
- Mr. Georgios TerzisChief Financial Officer · born 1983
- Mr. Nikolaos BardakisChief Operating Officer · born 1969
- Mr. Demetrios G. DemetriadesSecretary & Independent Director · born 1965
- Prof. Dimitrios TrafalisHead of Oncology